
Contents

Biology of Schizophrenia

M.S. Keshavan, R. Ganguli (Pittsburgh, Pa.)	1
Introduction	1
Definition of Schizophrenia	2
The Boundary of Schizophrenia	2
Classification of Schizophrenic Subtypes	2
Pathology and Pathophysiology	3
Structural Abnormalities	3
Physiological Dysfunctions	5
Biochemical Changes in Schizophrenia	8
Endocrinology of Schizophrenia	12
Neuropsychological Dysfunction	13
'Soft' Neurological Signs in Schizophrenia	14
Etiological Factors in Schizophrenia	14
Genetic Factors in Schizophrenia	14
Perinatal Influences	16
Autoimmune Hypothesis	16
Viral Hypothesis	20
Summary and Conclusions	23
References	24

Treatment of Schizophrenia

J.M. Davis, J.R. Barter (Chicago, Ill.)	34
Development of the Controlled Clinical Trial	34
Efficacy	35
Time Course	36
Do Antipsychotics Alter the Natural Course of Schizophrenia?	36
Comparative Efficacy and Spectrum of Different Antipsychotics	38
Indications	40
Relationship of Dose to Clinical Response	41

Psychological Effects of Antipsychotics	45
Long-Term Maintenance Effects of Antipsychotics	46
Time Course of Relapse of Schizophrenia	48
Indications for Maintenance Treatment	50
Targeted Treatment	51
Depot Long-Acting Antipsychotics	52
Mechanism of Action	53
Combined Antipsychotic with Other Treatment	55
Physical Treatment	55
Psychosocial and Drug Treatment for Psychosis	56
Inpatient Studies	56
Outpatient Studies	58
References	61

Serotonin in Psychiatric Pathophysiology

A Review of Data from Experimental and Clinical Research

E. Eriksson (Göteborg), M. Humble (Dandryd)	66
---	----

Anatomy and Function of Brain Serotonergic Neurons	66
Serotonin Receptors	68
Introduction	68
5-HT _{1A} Receptors	69
5-HT _{1B} Receptors	70
5-HT _{1C} Receptors	71
5-HT _{1D} Receptors	71
5-HT ₂ Receptors	71
5-HT ₃ Receptors	72
5-HT Receptors: Concluding Remarks	72
Effects of Different Psychoactive Treatments on Serotonin Neurotransmission	73
Tryptophan, 5-HTP, and Pyridoxin	73
Selective and Nonselective Serotonin Reuptake Inhibitors	74
Monoamine Oxidase Inhibitors	78
Lithium	79
Electroconvulsive Treatment	80
Serotonin and Animal Models of Anxiety	80
Assessment of Brain Serotonergic Activity in Man: Methodological Aspects	81
Plasma Concentrations of Tryptophan	81
Serotonin-Related Markers in Platelets	82
CSF-5-HIAA Concentrations	83
Serotonin-Related Neuroendocrine Markers	83
Serotonin-Related Markers: Concluding Remarks	85
Serotonin and Depression	85
Serotonin and Symptomatology of Depression	85
Serotonin-Related Biological Markers in Depression	86
Serotonin and Depression: Pharmacological Aspects	87
Serotonin and Depression: Concluding Remarks	88

Obsessive Compulsive Disorders	89
Serotonin and Symptomatology of OCD	89
Serotonin-Related Biological Markers in OCD	89
Serotonin and OCD: Pharmacological Aspects	90
Serotonin and OCD: Concluding Remarks	91
Panic Disorder	92
Serotonin and Symptomatology of Panic Disorder	92
Serotonin-Related Biological Markers in Panic Disorder	92
Serotonin and Panic Disorder: Pharmacological Aspects	93
Serotonin and Panic Disorder: Concluding Remarks	96
Additional Psychiatric Disorders Possibly Related to Serotonin	96
Over-Eating	96
Impaired Impulse Control	97
Premenstrual Syndrome	99
Social Phobia	100
Specific Side Effects of Drugs Facilitating Serotonin Neurotransmission	100
Serotonin in Psychiatric Pathophysiology: Concluding Remarks	101
References	102

Norepinephrine and Depression: A Reappraisal

S. Kindler, B. Lerer (Jerusalem)	120
Brain NE: Anatomy, Physiology and Behavior	121
Anatomy of Brain NE Systems	121
Physiology of Brain NE Systems	122
Behavioral Models and the NE System	123
Studies of the NE System in Depressed Patients	125
Studies of NE and Its Metabolites in the Periphery	125
Central Studies of NE and Its Metabolites	126
NE Studies in Postmortem Brains of Suicides and Depressed Patients	127
NE Receptor Sensitivity Studies in Depression	128
Challenge Tests to Assess Adrenergic Receptor Function in vivo	129
Conclusions	131
References	134

Antidepressants in the Treatment of Depression

W.F. Boyer, J.P. Feighner (Encinitas, Calif.)	142
Choice of Drug	143
Side Effect Considerations in Drug Selection	146
Dosing Strategies	147
Managing Side Effects	148
Tolerance	150
Stopping an Antidepressant	150
Nonresponse	151
New Antidepressants	154
References	156

Electroconvulsive Therapy

Efficacy, Side Effects and Mechanisms of Action

D.P. Devanand, H.A. Sackeim (New York, N.Y.)	170
Clinical Features and Indications	170
The Efficacy of Electroconvulsive Therapy	172
Psychological Theories	172
Relative Efficacy	176
Cognitive Side Effects	178
Electroconvulsive Therapy versus Antidepressant Medications	179
Frequency of Electroconvulsive Therapy	180
Relapse following Response to Electroconvulsive Therapy	181
Maintenance of Electroconvulsive Therapy	182
Mechanisms of Efficacy	182
Characteristics of the Seizure	183
Biochemical Changes	184
Hypothalamic and Hormonal Mechanisms	184
Neurotransmitter Systems	185
Norepinephrine	186
Adrenergic Receptor Effects	186
Serotonin	187
Dopamine	188
Acetylcholine	189
Endogenous Opioids	189
Gamma Aminobutyric Acid	190
Adenosine	192
Neurophysiology	192
Anticonvulsant Properties	192
Cognitive Effects	193
Mechanisms Underlying Electroconvulsive Therapy-Induced Cognitive Impairment	195
Neuropathology	196
Summary and Conclusions	197
Efficacy and Side Effects	197
Mechanisms	198
References	199

The Mood-Stabilizing Drugs

A.K. Jain (Kansas City, Mo.), S. Kelwala (Northville, Mich.), D. Willsie (Kansas City, Mo.)	211
Lithium	213
Anticonvulsants as Mood-Stabilizing Agents	215
Valproic Acid	219
Clonazepam	221
Verapamil-Calcium Channel Blockers	223

Serotonergic Agents: Tryptophan	225
Adrenergic Agents in Mania: Clonidine	228
Propranolol in Mania	229
Cholinergic Agents in Mania	231
Dopaminergic Agents in Manic-Depressive Illness	231
Conclusion	233
References	234

Neurobiological Mechanisms of Human Anxiety

D.S. Charney, S.W. Woods, J.H. Krystal (New Haven, Conn.), G.R. Heninger (West Haven, Conn.)	242
Neuroanatomical Substrates for Anxiety or Fear	242
The Role of Noradrenergic Function in Human Anxiety	244
Clinical Investigations of Noradrenergic Function in Anxiety Disorders	249
A Noradrenergic Neurodevelopmental Theory of Panic Disorder	251
Noradrenergic Function and the Mechanism of Action of Antipanic Treatment	253
The Role of Serotonin Function in Human Anxiety	254
Preclinical Investigations	255
Neuroanatomical Substrates for Anxiety of Fear and Their Relation to the Serotonin Hypothesis of Anxiety	256
Laboratory Animal Behavioral Models of Anxiety and Fear: Relationship to Sero- tonin Function	257
Clinical Investigations of Serotonin Function in Anxiety Disorders	258
Efficacy and Mechanism of Serotonin Specific Drugs in Anxiety Disorders	259
Current Status of the Serotonin Hypotheses of Human Anxiety	260
The Role of the Benzodiazepine-GABA System in Anxiety	261
Preclinical Investigations	261
Clinical Investigations	262
The Benzodiazepine Receptor and the Mechanism of Anxiolytic Action of Benzodi- azepines	264
Implications of Benzodiazepine Anxiolytic Efficacy for the Pathophysiology of Anx- iety Disorders	265
Adenosine Function and Panic Anxiety	266
The Role of Dopamine Neuronal Activity in Anxiety	267
The Role of Corticotrophin-Releasing Hormone in Anxiety	267
Lactate Induction of Panic Attacks	268
Brain Imaging during Panic Attacks	268
Concluding Remarks	268
References	270

Biological Treatment of Anxiety Disorders

R. Balon, R. Pohl, V.K. Yeragani (Detroit, Mich.)	284
Panic Disorder	285
Tricyclic Antidepressants	285
Second Generation Antidepressants	287

Monoamine Oxidase Inhibitors	288
Benzodiazepines	289
β -Blocking Agents	291
Azaspirodecanediones	292
Miscellaneous Drugs	292
Generalized Anxiety Disorder	293
Benzodiazepines	294
Tricyclic Antidepressants	295
β -Blocking Agents	296
Azaspirodecanediones	297
Performance Anxiety	298
Social Phobia	299
Obsessive-Compulsive Disorder	300
Post-Traumatic Stress Disorder	301
Conclusion	302
References	303
Subject Index	311